.jpeg)
2026-08-14 02:50:16
Sotorasib (brand name Lumakras) is the world's first approved targeted drug for KRAS G12C mutations, used in precision treatment of non-small cell lung cancer and colorectal cancer. This article explains its efficacy limits, approved indications, mechanism of action, and safety considerations to help patients set realistic treatment expectations.
2026-08-13 04:17:25
Trametinib is a highly selective MEK1/2 inhibitor used in BRAF V600-mutant melanoma, NSCLC, low-grade glioma, and other solid tumors. This article details refrigeration requirements, fasting dosing protocols, missed-dose management, eligible patient populations, and special-population considerations to support safe and standardized treatment.
2026-08-13 03:58:16
Belzutifan (brand name Welireg) is the first oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, holding a unique position in managing VHL disease-associated tumors and clear cell renal cell carcinoma. This article systematically reviews its phased treatment strategy, survival outcomes, efficacy-modifying factors, adverse event management, and special-population considerations.
2026-08-12 04:21:50
Pemigatinib and Anlotinib are both anti-tumor targeted agents, yet they differ fundamentally in mechanism, target specificity, and applicable cancer types. This article provides a systematic comparison across molecular mechanisms, indications, precision, adverse effects, and treatment selection to guide informed clinical decisions.
2026-08-11 05:57:10
Lapatinib is an oral small-molecule tyrosine kinase inhibitor targeting HER2 and EGFR pathways in HER2-positive breast cancer. This article clarifies its therapeutic positioning, clinical applications, and the critical role of HER2 testing in treatment decisions.
2026-08-11 05:22:22
Lapatinib is an oral HER2-targeted anticancer agent. This article covers dosing schedule, food interactions, combination regimens, missed-dose management, drug interactions, and safety monitoring for patients with HER2-positive breast cancer.
2026-08-10 07:50:50
Capivasertib (Truqap) is the first-in-class selective AKT inhibitor approved in combination with fulvestrant for HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN alterations. This guide covers indications, recommended dosing, special populations, warnings, drug interactions, and adverse event management.
2026-08-10 07:34:19
Cemiplimab is a PD-1 immunotherapy drug used for advanced skin cancers and non-small cell lung cancer. As a biologic agent, it requires strict refrigeration at 2°C to 8°C, protection from freezing, light, and agitation to maintain drug stability and efficacy.
2026-08-07 07:30:56
Mavacamten is the first cardiac myosin inhibitor targeting the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM). This article reviews its treatment duration, clinical efficacy, head-to-head comparisons with conventional therapies, and long-term management strategies.
2026-08-07 07:13:02
Belzutifan is the first approved hypoxia-inducible factor-2α (HIF-2α) inhibitor, indicated for VHL disease-associated tumors, advanced renal cell carcinoma, and pheochromocytoma/paraganglioma. This article provides a systematic overview of its approved indications, adult and pediatric weight-based dosing, administration guidelines, drug interactions, and safety monitoring requirements to support standardized clinical use.
2026-08-07 06:55:55
Encorafenib is an oral selective BRAF V600 kinase inhibitor used in combination with binimetinib or cetuximab for BRAF-mutant melanoma, metastatic colorectal cancer, and non-small cell lung cancer. This article provides a systematic review of its label highlights, tumor-specific dosing schedules, administration timing, drug interactions, and special population guidance to support standardized clinical use.
2026-08-06 07:53:13
Alpelisib (Piqray) and inavolisib (Itovebi) both target the PI3Kα pathway in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, yet their approved indications, combination partners, and evidence bases differ. This article compares the two agents across treatment line, clinical evidence, and safety considerations.
